The treatment involves taking an oral solution of citicoline at a dose of 1000 mg per day. The medication will be given for a period of 6 months after the surgery. During this time, the study will monitor how well patients maintain their cognitive abilities, which includes functions like memory, attention, and problem-solving skills.

Throughout the study, participants will undergo various assessments of their mental function and physical abilities. The main evaluation will occur 6 months after starting the treatment using a comprehensive cognitive test called the Montreal Cognitive Assessment (MoCA). The study will also track any side effects that might occur during the treatment period.

The purpose of the study is to see if a structured lifestyle program combined with Metformin can help maintain or improve cognitive function in older adults. Participants will be randomly assigned to either an active group receiving the structured lifestyle program and Metformin or a control group receiving a self-guided lifestyle program and a placebo. The lifestyle program includes guidance on diet, exercise, and other healthy habits. The study will last for 24 months, during which participants will be monitored for changes in their cognitive abilities and overall health.

Throughout the study, various aspects of health will be assessed, including memory, thinking skills, physical activity, diet, and quality of life. The trial aims to provide valuable insights into whether combining lifestyle changes with Metformin can effectively reduce the risk of developing dementia in older adults. Participants will be closely monitored to ensure their safety and well-being throughout the study period.

The research aims to understand how these different imaging tracers work in people with various cognitive conditions, including Mild Cognitive Impairment, Alzheimer’s Disease, Frontotemporal Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Dementia with Lewy Bodies, and Down’s Syndrome. Each participant will receive the imaging substances through an injection into a vein.

During the study, participants will undergo several brain scans. The imaging substances will be given in very small amounts and are designed to attach to tau proteins in the brain, making them visible during the scanning procedure. These scans will help researchers compare how well each tracer works in showing tau protein buildup in different brain areas over time.

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

The purpose of the study is to understand how donepezil hydrochloride affects cognitive and motor functions, which are related to thinking and movement, in older adults. Participants will be asked to perform tasks that require both thinking and physical movement, known as dual-task activities. The study will measure how well participants perform these tasks after taking either the medication or the placebo. Additionally, the study will use a technique called MRI (Magnetic Resonance Imaging) to observe brain activity during these tasks.

The trial will take place over a short period, with participants attending two visits. During these visits, they will complete various tests to assess their cognitive and motor skills. The results will help researchers understand the potential benefits of donepezil hydrochloride in improving brain function in older adults. This study is important for exploring new ways to support healthy aging and cognitive health.

The purpose of the study is to evaluate how well EGb 761® works compared to a placebo in improving cognitive function in individuals with cognitive impairment due to post-COVID-19 syndrome. Participants in the study will be randomly assigned to receive either the Ginkgo biloba extract or a placebo. The study will last for 12 weeks, during which participants will take the tablets daily. Throughout the study, participants will undergo various tests to assess changes in their cognitive abilities, such as memory and attention, as well as their overall well-being.

Participants will be monitored for any side effects or adverse reactions to the treatment. The study aims to provide valuable information on whether Ginkgo biloba extract can help improve cognitive function in those affected by post-COVID-19 syndrome. This research could potentially lead to new treatment options for individuals experiencing long-term cognitive issues after recovering from COVID-19.

Participants in the study will receive either Phenserine or Donepezil over a period of several weeks. Phenserine is taken in capsule form, while Donepezil is available as film-coated tablets. The study will monitor changes in specific markers in the body that are linked to Alzheimer’s disease, as well as the safety and tolerability of the medications. Participants will be observed for any side effects and changes in their health during the study.

The study will also assess how well participants adhere to the treatment schedule and any changes in their cognitive abilities, such as memory and attention, using various tests. The goal is to better understand the potential benefits and risks of these medications in treating early or mild Alzheimer’s disease.

Participants in the study will receive either the active drug NTRX-07 or a placebo, which looks like the active drug but does not contain the active substance. The study is designed to be “double-masked,” meaning neither the participants nor the researchers will know who is receiving the active drug or the placebo during the trial. This helps ensure that the results are not influenced by expectations about the treatment.

The trial will also look at how the body processes NTRX-07 by studying its presence in the blood and cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord. The study will last for a total of 28 days, during which participants will be closely monitored for any side effects or changes in their condition. The goal is to gather information that could help in developing effective treatments for Alzheimer’s Disease and Mild Cognitive Impairment in the future.

The purpose of the study is to better understand how the contrast agent moves within the brain. This helps in assessing where there might be blockages in the flow of cerebrospinal fluid and how quickly substances are cleared from the brain. Participants will receive the contrast agent through a procedure called intrathecal use, which means it is injected into the space around the spinal cord. After the injection, MRI scans will be performed to track the distribution and intensity of the contrast agent over time.

The study aims to provide valuable insights into the treatment and management of these brain and spinal fluid conditions by observing changes in the MRI signal after the contrast is administered. This information could potentially lead to improved diagnostic and therapeutic strategies for patients with these conditions.

The study involves several types of GBCAs, including Gadoxetic Acid, Disodium, Gadoteridol, Gadobenate Dimeglumine, Gadoteric Acid, and Gadobutrol. Participants in the study will receive these agents through an intravenous injection, which means the substance is delivered directly into a vein. The purpose of the study is to assess whether repeated exposure to these agents affects the participants’ motor and cognitive functions over time. Participants will undergo regular MRI scans and other assessments to monitor any changes in their health.

Throughout the study, participants will be monitored for any adverse effects, which are any unwanted or harmful effects that may occur after taking a medication or undergoing a procedure. Blood and urine samples will be collected to measure the levels of gadolinium in the body. The study aims to provide valuable insights into the safety and long-term effects of using GBCAs in medical imaging, helping to ensure that these agents are used safely in the future.

The purpose of the study is to evaluate how 24 months of treatment with lithium carbonate can impact the behavior and quality of life of individuals with TBR1-related neurocognitive disorder. Participants will first undergo an observation period lasting between 6 to 12 months. Following this, they will receive lithium carbonate treatment for 24 months. During this time, researchers will monitor changes in adaptive behavior, which refers to how well a person can adjust to their environment and daily life activities.

Throughout the study, participants will be assessed at various intervals to track improvements in socialization, communication, and overall quality of life. The study will also look at any side effects related to lithium carbonate and changes in brain activity. This research aims to provide valuable insights into the potential benefits and safety of using lithium carbonate for individuals with TBR1-related neurocognitive disorder.

Participants in the study will take lamivudine in the form of a film-coated tablet. The study will last for 24 weeks, during which time participants will be monitored for changes in specific markers in their blood. These markers include proteins and genes that are associated with cognitive function and the body’s immune response. The study will also track any side effects that may occur during the treatment period.

Throughout the study, participants will have regular visits to the study center to undergo various tests and assessments. These visits are designed to monitor the effects of the treatment on their cognitive abilities and overall health. The study aims to provide valuable insights into the potential benefits of lamivudine for individuals with MCI due to Alzheimer’s Disease.

Participants in the study will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will last for 12 weeks, during which time the effects of the treatment on cognitive function will be assessed. This will be done using a series of tests that measure different aspects of cognitive performance. The study will also look at changes in depression, anxiety, and quality of life over the course of the treatment.

In addition to the main focus on cognitive function, the study will also monitor changes in depression and anxiety levels, as well as overall quality of life. These aspects will be evaluated at the start of the study and again at 12 and 24 weeks to see if there are any improvements. The study aims to provide valuable information on how treating iron deficiency in patients with chronic heart failure can impact their mental and emotional well-being.

The purpose of the study is to assess whether Fasudil Hydrochloride can help prevent memory loss in people with early Alzheimer’s disease. The study will last for 12 months, during which participants will take the medication in capsule form by mouth. Throughout the study, participants will undergo various assessments to monitor their memory, attention, and overall brain function. These assessments will help researchers understand the potential benefits of Fasudil Hydrochloride in slowing down the progression of Alzheimer’s disease.

Participants will also have regular check-ups to ensure their safety, including physical and neurological examinations, as well as tests like ECG (a test that checks the heart’s electrical activity) and blood tests. The study will also look at changes in certain markers in the body that are related to Alzheimer’s disease. By the end of the study, researchers hope to gather valuable information on the effectiveness and safety of Fasudil Hydrochloride for treating early Alzheimer’s disease.

The purpose of the study is to see if EMONO can help improve depressive symptoms in people who have not responded well to at least one standard antidepressant. Participants will receive the treatment through inhalation, which means breathing in the gas. The study will last for several weeks, during which participants will be monitored for changes in their depressive symptoms and overall well-being. The main focus will be on how symptoms change from the start of the study to four weeks later.

Throughout the study, participants will have regular check-ups to assess their mood and any side effects they might experience. The study aims to provide valuable information on whether EMONO can be a helpful addition to existing treatments for depression in people with neurocognitive disorders. This research could lead to better treatment options for those living with these challenging conditions.

Participants in the study will receive midazolam in the form of a gel that is taken orally. The study will compare the effects of this treatment with a placebo to see if it helps reduce resistance to care. The trial will monitor changes in the patients’ behavior and their acceptance of care, as well as any side effects that may occur. The study will also assess the overall experience of the caregivers providing the treatment.

The trial will take place over a period of time, during which patients will be observed for any improvements in their ability to accept care and any changes in their symptoms. The goal is to find out if midazolam can make it easier for patients with severe neurocognitive disorders to receive the medical attention they need.

The purpose of the study is to evaluate the safety and effectiveness of RL-007 in improving cognitive performance in participants diagnosed with schizophrenia. Participants will be randomly assigned to receive either RL-007 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will last for a period of six weeks, during which participants will take the medication orally and attend regular study visits for assessments.

Throughout the study, participants will undergo various tests to measure changes in their cognitive abilities, such as memory and attention, as well as overall health checks, including vital signs and laboratory tests. The study aims to provide valuable information on whether RL-007 can help improve cognitive function in people with schizophrenia, potentially leading to better treatment options in the future.

Participants in the study will undergo a tau PET scan, which is a type of imaging test that helps doctors see changes in the brain. This test will be compared to other diagnostic methods to see if it provides better information. The study will look at how the use of tau PET affects the diagnosis, the confidence of doctors in their diagnosis, and the management of the patient’s condition. It will also assess how this imaging technique impacts the patient’s wellbeing, including their levels of anxiety and uncertainty.

The study will also explore how tau PET compares to new blood tests and artificial intelligence tools in diagnosing these conditions. The goal is to see if tau PET can offer a more reliable way to understand and manage mild cognitive impairment and dementia, ultimately improving the care and quality of life for patients with these conditions.